menu
    • menu
    [{"orgOrder":0,"company":"BITT","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"BITT-101","moa":"CD40","graph1":"Immunology","graph2":"Preclinical","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"BITT \/ National Institutes of Health"},{"orgOrder":0,"company":"BITT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BITT-CD4D11","moa":"CD40","graph1":"Immunology","graph2":"Preclinical","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"BITT \/ Undisclosed"},{"orgOrder":0,"company":"BITT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BITR2101","moa":"TNF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BITT \/ Undisclosed"},{"orgOrder":0,"company":"BITT","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"BITR2101","moa":"TNF2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ BITT","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ BITT"},{"orgOrder":0,"company":"BITT","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"BITR2101","moa":"||TNF2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ BeiGene"},{"orgOrder":0,"company":"BITT","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"BITD401412","moa":"Undisclosed","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ McQuade Center","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ McQuade Center"},{"orgOrder":0,"company":"BITT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BITT-2101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by BITT

    Menu

    BITT

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BITD401412

                            Therapeutic Area : Endocrinology

                            Study Phase : IND Enabling

                            Sponsor : McQuade Center

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BITT Announces CD40 Otsuka Deal and New NIH Funding For TNFR2 Clinical Trial

                            Details : MSRD will finance key non-human primate studies for the pre-clinical development of BITT’s CD40 antagonist, BITD401412, in autoimmune diseases, including autoimmune thyroiditis, T1D & IBD.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 16, 2024

                            Lead Product(s) : BITD401412

                            Therapeutic Area : Endocrinology

                            Highest Development Status : IND Enabling

                            Sponsor : McQuade Center

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BITR2101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lym...

                            Details : BITR2101 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 26, 2024

                            Lead Product(s) : BITR2101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BITT-101

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            BITT Announces NIH Award for Advancement of Anti-CD40 Antibody

                            Details : The funding will support the preclinical development of BITT’s BITT-101, a novel dominant CD40 antagonist antibody for use in the treatment of Sjögren’s Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 31, 2023

                            Lead Product(s) : BITT-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BITT-2101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BITT Announces FDA Acceptance of IND for TNFR2 Antibody

                            Details : BITT2101 is an investigational, novel, tumor necrosis factor superfamily receptor (TNFSR) antagonist antibody, which is being investigated for the treatment in patients with relapsed or refractory Non-Hodgkin’s lymphomas.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 18, 2023

                            Lead Product(s) : BITT-2101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BITT-CD4D11

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BITT Provides Update on DOMab Platform and CD40 Program

                            Details : BITT-CD4D11 and BITT-CD4F10, CD40 antagonists, are being developed for indications in autoimmunity and inflammation including Crohn’s disease, inflammatory bowel disease, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 13, 2023

                            Lead Product(s) : BITT-CD4D11

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BITR2101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : KBI Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT’s Lea...

                            Details : The agreement focuses to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and infectious diseases.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 09, 2021

                            Lead Product(s) : BITR2101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : KBI Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            BITT

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BITR2101,Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : BeOne Medicines

                            Deal Size : $125.6 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Boston Immune Technologies and Therapeutics and BeiGene Enter into an Option and License Agreement to Develop ...

                            Details : BeiGene has secured an option to an exclusive license to develop, manufacture, and commercialize BITT’s TNFR2 antagonist antibodies in Asia (ex-Japan), Australia, and New Zealand. Parties plan to conduct Phase 1 trials of BITR2101 and combination studi...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            February 17, 2021

                            Lead Product(s) : BITR2101,Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : BeOne Medicines

                            Deal Size : $125.6 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth